ReviewPediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology2026
Gastrointestinal manifestations during oral immunotherapy: A guide for pediatric allergists.
Review in Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gastrointestinal manifestations during oral immunotherapy: A guide for pediatric allergists.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral immunotherapy (OIT) is a promising therapeutic strategy for desensitizing patients with immunoglobulin E (IgE)-mediated food allergies. Although effective, OIT is frequently associated with adverse events (AEs), and gastrointestinal (GI) manifestations are among the most common and challenging AEs, which are the leading cause of OIT discontinuation. These reactions range from immediate IgE-mediated signs and symptoms to delayed, non-IgE-mediated, eosinophil-associated disorders, including eosinophilic esophagitis (EoE). While systemic reactions, such as anaphylaxis, are well-known concerns, GI manifestations are frequently encountered, although they are often less severe than systemic reactions. A thorough understanding of GI signs and symptoms is therefore essential for patients and clinicians to navigate OIT effectively. This narrative review provides a comprehensive overview of GI AEs observed during OIT, detailing their clinical presentation, underlying pathophysiology, and evidence-based management approaches. A clear understanding of these manifestations and their management is essential for optimizing patient safety and treatment adherence in the era of OIT.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.